Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to initiate a Phase I clinical trial of Precigen’s PRGN-2012, a first-in-class, investigational off-the-shelf (OTS) AdenoVerse™ immunotherapy in adult patients with recurrent respiratory papillomatosis (RRP).
RRP is a rare, difficult-to-treat, and sometimes fatal neoplastic disease of the upper and lower respiratory tracts caused by human papillomavirus (HPV) type 6 (HPV 6) or HPV type 11 (HPV 11).1-4
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen’s vision is to develop life-saving and cost-conscious therapies utilizing our cutting-edge therapeutic and platform technologies for patients with unmet medical need.
Precigen’s mission is to discover, develop and commercialize next generation gene and cell therapies focused in immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen has offices/labs located at the VTCRC, Blacksburg, VA.
The Virginia Tech Corporate Research Center is an integral part of Virginia’s innovation ecosystem. Located a stone’s throw from Virginia Tech, one of the nation’s premier research universities, VTCRC is where bold thinkers turn big ideas into world-changing realities. VTCRC features flexible-lease wet and dry research labs, modern offices, and coworking space, all with top-tier amenities.
Nestled in the beautiful New River Valley, the VTCRC ecosystem exists alongside an affordable cost of living, high-quality education systems, and modern healthcare facilities. It’s no wonder VTCRC is leading the way in biotech, autonomous tech, software, and aerospace. Because VTCRC is adjacent to Virginia Tech, companies have access to an elite talent pool of students, faculty, and staff and university resources.
What sets VTCRC apart is its commitment to collaboration as the driving force behind innovation. Entrepreneurs, startups, and seed companies who become part of the innovation ecosystem have access to a rich environment of resources to take their ideas from lab to market. From Virginia Tech’s Link + License + Launch, to the Roanoke Regional Accelerator Program, to a national STEM research accelerator, VTCRC connects researchers with investors and business experts to disrupt markets and improve lives.